ARTICLE | Clinical News
Tykerb lapatinib: Phase III started
March 3, 2008 8:00 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Tykerb lapatinib ( Tyverb) Business: Cancer Molecular target: Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1); Epidermal growt...